| 09:00-10:30 |
S2: New Challenges in Treatment of Hypertension
Chairs: Stefan Agewall, Norway; Antonio Coca, Spain;
Yehonatan Sharabi, Israel
|
Hall A |
|
Joint Session with ESC Council on Hypertension |
| 09:00 |
Best Therapy for Resistant Hypertension: The Pathway Study
Antonio Coca, Dept. of Hypertension & Vascular Risk Unit Hospital Clinic (IDIBAPS). University of Barcelona, Spain
|
| 09:20 |
Comparing the Results of Pharmacotherapy vs. Device Intervention in Resistant Hypertension
Sverre Kjeldsen, Dept. of Cardiology, University of Oslo Ullevaal Hospital, Norway
|
| 09:40 |
When to Start the Treatment of Arterial Hypertension?
Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Spain
|
| 10:00 |
The Changing Pattern of Hypertension Treatment: Arterial Properties and Hemodynamics
Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel
|
| 10:20 |
Q & A |
|
| 10:30-11:00 |
Coffee Break, Networking, Exhibition Visit and Posters Viewing |
|
| 11:00-12:30 |
S3: Hot Topics in Heart Failure
Chairs: Gad Keren, Israel; Christian Torp-Pedersen, Denmark |
Hall A |
|
| 11:00 |
Debate: Entresto should be First Line Therapy in HFrEF
Pro: Petar Seferovic, Dept. of Cardiology, Belgrade School of Medicine, Serbia
Con: Giuseppe M.C. Rosano, Cardiovascular Clinical Academic Group, St George’s Hospital NHS Trust Medical School, London, UK |
| 11:25 |
Debate: SGLT2 Inhibitors for Type 2 Diabetes Mellitus: Do we need HF Specific Trials?
Pro: Itamar Raz, Diabetes Unit at Hadassah University Hospital, Jerusalem, Israel
Con: Claudio Ceconi, Dept. of Cardiology, University Hospital of Ferrara, Ferrara, Italy
|
| 11:50 |
Debate: Beta-Blockers and Digoxin can benefit HFrEF Patients with Atrial Fibrillation
Pro: Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
Con: Mitja Lainscak, Dept. of Cardiology, General Hospital Celje, Slovenia
|
| 12:15 |
Obesity in Heart Failure: Update 2016
Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany |
| 12:30 |
Light Lunch |
| 13:00-14:00 |
Satellite 1: Novartis on Heart Failure
Chairs: Felipe Martinez, Argentina; Jean Marc Weinstein, Israel |
Hall A |
| 13:00 |
Role of Neprilysin Inhibitors in CV Disease: What can we Learn from PARADIGM?
Petar Seferovic, Dept. of Cardiology, Belgrade School of Medicine, Serbia |
| 13:30 |
Heart Failure Guidelines 2016: What is New?
Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
|
| 13:45 |
Panel Discussion: Which Patients and when to use Sacubitril/Valsartan (Entresto)?
Offer Amir, Tuvia Ben Gal, Israel Gotsman, Andre Keren, Avi Shotan, Israel
|
|
| 14:00-15:00 |
Satellite 2: Boehringer on Diabetes Mellitus
Chairs: Avraham Karasik, Israel
|
Hall A |
| 14:00 |
Diabetes Therapy: From Glucocentric to Complications-Oriented Approach
Avraham Karasik, Israel |
| 14:40 |
Panel Discussion: Which Patients and when to use Empagliflozin?
Rakefet Bacharach, Avraham Karasik, Yoseph Rozenman, Israel |
|
| 15:00-16:00 |
S6: Myocardial and Pericardial Disease: A Case Based Approach to Patient Management
Chairs: Yehuda Adler, Israel; Stefan Agewall, Norway;
Andre Keren, Israel
|
Hall A |
|
Joint Session with ESC Working Group on Myocardial and Pericardial Disease |
|
| 15:00 |
Clinically Suspected Myocarditis with Heart Failure Treatment
Shemy Carasso, Baruch Padeh Medical Center, Poriya, Israel |
| 15:20 |
Atrial Fibrillation, Treatment with NOAC and Pericarditis: Treatment? Follow-Up?
Daniel Monakier, Israel
|
| 15:40 |
Pericarditis: Treatment? Follow-Up?
Dor Lotan, Sheba Medical Center, Tel Hashomer, Israel
|
|
| 16:00-16:30 |
Coffee Break, Networking, Exhibition Visit and Posters Viewing |
|
| 16:30-18:00 |
S7: New Directions in Heart Failure
Chairs: Stefan Agewall, Norway; Stefan Anker, Germany |
Hall A |
|
Joint Session with Heart Failure Association of the ESC |
| 16:30 |
Potassium Lowering Drugs
Mitja Lainscak, Dept. of Cardiology, General Hospital Celje, Slovenia
|
| 16: 50 |
Iron Therapy
Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
|
| 17:10 |
New Therapies for Acute Decompensated Heart Failure
Giuseppe Rosano, Cardiovascular Clinical Group, St. George’s Hospital NHS Trust Medical School, London, UK |
| 17:40 |
Non-Pharmacologic Therapies for Advanced Heart Failure
Offer Amir, Dept. of Cardiology, Baruch Padeh Medical Center, Poriya, Israel
|
| 18:00-19:30 |
Get Together Cocktails |
|
|
| Monday, 30 May, 2016 |
| 08:00 |
Registration |
| 08:30-09:30 |
S8: Gender Differences in Cardiovascular Pharmacotherapy
Chairs: Claudio Ceconi, Italy; Mady Moriel, Israel;
Zvi Vered, Israel
|
Hall A |
| 08:30 |
Gender Differences in Pharmacology
Thomas Walther, Dept. of Pharmacology & Therapeutics, University College Cork, Ireland
|
| 08:45 |
Gender Differences in Clinical Trials
Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain
|
| 09:00 |
Gender Differences in Cardiovascular Side Effects
Giuseppe Rosano, Cardiovascular Clinical Academic Group, St George’s Hospital NHS Trust Medical School, London, UK
|
| 09:15 |
Gender Differences in Treatment Delivery
Avital Porter, ICCU and The Women’s Cardiac Health Clinic, Rabin Medical Center-Beilinson, and the Sackler Faculty of Medicine, Tel Aviv, Israel |
|
| 09:30-10:00 |
S9: Special Lecture: Breaking News – ESC 2016 Prevention Guidelines
Chairs: Stefan Agewall, Norway; Yoseph Shemesh, Israel |
Hall A |
| 09:30 |
What is New in the 2016 European ESC Guidelines on Cardiovascular Disease Prevention?
Arno W. Hoes, University Medical Center Utrecht, The Netherlands |
| 10:00-10:30 |
Coffee Break, Networking, Exhibition Visit and Posters Viewing |
| 10:30-11:30 |
S10: Individualizing Antithrombotic Therapy
Chairs: L. Buryachkovskaya, Russia, Nikita Lomakin, Russia, Alexander Niessner, Austria
|
Hall A |
|
Russian Scientific Inflammation Society, Central Clinical Hospital of the Presidential Department of Russian Federation |
| 10:30 |
Laboratory Monitoring of Antiplatelet Therapy
Nikita Lomakin, Russia |
| 10:50 |
Genetic Aspects of Antithrombotic Therapy
Alexey Meshkov, Russia |
| 11:10 |
Role of Local Inflammation in the Development of Instent Restonosis
Zufar Gabbasov, Russia |
|
| 11:30-13:00 |
S11: Critical Issues in Antithrombotic Therapy: 2016 Update
Chairs: Stefan Agewall, Norway; Joao Morais, Portugal;
Amit Segev, Israel
(Supported by an Unrestricted Educational Grant from AstraZeneca) |
Hall A |
|
Joint Session with ESC Working Group on Thrombosis |
| 11:30 |
DAPT Duration after Stenting in Stable CAD
Sven Wassmann, Dept. of Cardiology, Isar Heart Center, Isar Klinikum, Munich, Germany
|
| 11:45 |
DAPT Duration after Myocardial Infarction
Sigrun Halvorsen, Dept. of Cardiology, Oslo University Hospital, Ullevaal, Norway |
| 12:00 |
Antithrombotic Therapy in Patients with AF and ACS
Dan Atar, Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway
|
| 12:15 |
Should NOACs Totally replace VKA, Aspirin for Stroke Prevention in AF?
Joao Morais, Div. of Cardiology, Santo Andre’s Hospital, Leiria, Portugal |
| 12:30 |
Reversal Strategies for Non-VK Oral Anticoagulants
Alexander Niessner, Dept. of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria |
| 12:45 |
Light Lunch |
|
| 13:30-14:30 |
Satellite 3: Pfizer on NOACs
Chairs: Yoseph Rozenman, Israel |
Hall A |
| 13:30 |
Modern Stroke Prevention in Atrial Fibrillation: How to Risk Stratify the Patients? How to Treat the Elderly?
Dan Atar, Oslo, Norway |
| 13:50 |
The Future of Stroke Prevention in NVAF: NOACs for all ?
Roy Beinart, Tel Hashomer, Israel |
| 14:05 |
Which NOAC to whom? Translating the Data into Clinical Decisions
Michael Glikson, Tel Hashomer, Israel |
| 14:20 |
Panel Discussion: Stroke Prevention in NVAF Patients: Challenges in Clinical Practice |
|
| 13:30-14:30 |
Satellite 4: Amgen on Lipid Lowering
Chairs: Yaakov Henkin, Israel; Ran Kornowski, Israel |
Hall B |
| 13:30 |
New Era in Lipid Lowering Therapy: PCSK9 Inhibitors: Efficacy, Safety and Early Promise of CVD Event Reduction
Evan Stein, USA |
|
| 14:30-16:00 |
S12: Intersociety Opinion: New Drugs and Therapies
Chairs: Stefan Agewall, Norway; Michael Glikson, Israel; Felipe Martinez, Argentina
|
Hall A |
|
Joint Session with International Society of Cardiovascular Pharmacotherapy |
| 14:30 |
New Anti-Arrhythmics
George Dan, University of Medicine “Carol Davila”, Bucharest, Romania
|
| 14:50 |
New Anti-Thrombotics
Antoni Martínez Rubio, Dept. of Cardiology, University Hospital of Sabadell, Barcelona, Spain
|
| 15:10 |
New Drugs for Angina and CAD
Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain
|
| 15:30 |
New Drugs for Heart Failure
Felipe A. Martinez, Cordoba National University, Argentina
|
| 15:50 |
Conclusion |
|
| 14:30-16:00 |
S13: Focus Session: Temporal Trends, Treatments and Outcomes after ACS in Israel: The Israel National ACSIS Project
Chairs: Zaza Iakobishvili, Israel; Ran Kornowski, Israel |
Hall B |
|
Joint Session with the Israel Heart Society Working Group for Acute Cardiac Care |
| 14:30 |
ACSIS 2000-2013: Overview
Ilan Goldenberg, Sheba Medical Center and Tel Aviv University, Israel
|
| 14:50 |
Novel Oral P2Y12 Inhibitors Uptake: Insights from ACSIS 2013 and other Real Life Data
Roy Beigel, Israel
|
| 15:10 |
ACSIS 2000-2013: Reperfusion Strategies and Outcomes
Eli Lev, Rabin Medical Center and Tel Aviv University, Israel |
| 15:30 |
Panel Discussion: Moshe Flugelman, Israel; Shmuel Gottlieb, Israel;
Sigrun Halvorsen, Norway; Nikita Lomakin, Russia; Joao Morais, Portugal;
Sven Wassmann, Germany |
| 16:00 |
Conclusion |
|
| E-poster Presentations |
| 1. |
The Level of Uric Acid in Metabolic Syndrome Patient and Way of decreasing it
Olena Gerasymenko, National University of Pharmacy, Kharkiv, Ukraine |
| 2. |
In Type 2 Diabetics Insulin Therapy is Associated with Micro- But Not Macrovascular Events Independently of Clinical Risk or Coronary Artery Calcium Score – An 8 Year Follow-Up
David Halon, Dept. of Cardiovascular Medicine, Lady Davis Carmel Medical Centre and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Israel |
| 3. |
Reckless Administration of QT Interval Prolonging Agents in Elderly Patients with Drug-Induced Torsade De Pointes (TdP)
Dan Justo, Internal Medicine and Geriatrics D, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel |
| 4. |
Hypertension and Comorbidity: Reality Clinical Practice Data: Blood Pressure Control
Davyd Yakhontov, Novosibirsk Medical University, Russia |
| 5. |
Comparison of Antiplatelet Effects of Different Forms of Acetylsalicilicacid
Nikita Lomakin, Central Clinical Hospital of President Department of Russian Federation, Moscow, Russian Federation |
|
|
|
